TSH Biopharm established audit committee according to the Securities and Exchange Act in June 15, 2017. The Company’s audit committee is comprised of three independent directors.
The powers of the Audit Committee are as follows:
The main function of the Audit Committee is to supervise fair expression of the financial reports, the hiring (and dismissal), independence and performance of certificated public accountants, the effective implementation of the internal control system, compliance with relevant laws and regulations and management of the existing or potential risks.
Audit Committee shall convene at least once quarterly.
Please refer to our annual report for more information about the Audit Committee.The term of office of the current Audit Committee is from May 29, 2020 to May 28, 2023.
Wang, Chih-Li is the chairman of Audit Committee.
Huang, Yaw-Bin and Chen, Rwei-Syun are the members of Audit Committee.
Wang, Yi-Min, the former independent director of the Company, resigned on April 15, 2022. The by-election was held in the General Shareholders’ Meeting on May 25, 2022, and Huang, Yaw-Bin has been elected.